Senator Tim Kennedy joined pediatric hematologist/oncologist Steven Ambrusko MD, MS, at Roswell Park Comprehensive Cancer Center to urge the New York State Department of Health to expedite the coverage approval process for a new groundbreaking gene therapy that is being hailed as a cure for sickle cell disease.

St. Joseph’s Health and Roswell Park are proud to announce the launch of a groundbreaking Cancer Care service line, bringing exceptional oncology services to Central New York.

A single infusion of the CAR T cell therapy ciltacabtagene autoleucel produced deep, durable responses in multiple myeloma patients whose disease had progressed after initial therapy. Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park, shared the updated results in an oral abstract session at he American Society of Hematology (ASH) annual meeting.

Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL), report the authors of a phase 3 clinical trial sponsored by SWOG Cancer Research Network and being presented Sunday, Dec. 10, by senior author Kara Kelly, MD, Chair of Pediatric Oncology at Roswell Park Comprehensive Cancer Center, during the 2023 annual meeting of the American Society of Hematology in San Diego, California.